title: Prognostic implications of leg ulcers from hydroxycarbamide therapy in patients with essential thrombocythaemia.
abstract: Essential thrombocythemia (ET) is a clonal stem-cell disorder characterized by persistent thrombocytosis. Patients with ET and risk factors for thrombotic complications have been shown to benefit from cytoreductive therapy, the most common agent used being, hydroxycarbamide. Although this agent is usually well-tolerated, one of the recognized adverse effects is the development of leg ulcers. We undertook retrospective analysis of consecutive ET patients treated with hydroxcarbamide and identified several specific features for this complication including advanced age, female preponderance, reduced overall survival, tendency to develop future vascular events and intolerance to the second line agent, anagrelide.
authors.affiliation: Department of Haematology, Russells Hall Hospital, Dudley, UK. seb1976@liv.ac.uk
authors.forename: Sebastian
authors.initials: S
authors.lastname: Francis
authors.forename: David
authors.initials: D
authors.lastname: Bareford
authors.forename: Christina
authors.initials: C
authors.lastname: Baggott
authors.forename: Christina
authors.initials: C
authors.lastname: Baginott
authors.forename: Jecko
authors.initials: J
authors.lastname: Thachil
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects*; D007871:Leg Ulcer / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D013920:Thrombocythemia, Essential / Q000188:drug therapy*
chemical_list: D004791:Enzyme Inhibitors; D006918:Hydroxyurea